{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:28Z","timestamp":1784700388713,"version":"3.55.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Type 1 diabetes (T1D) is associated with increased risk of dementias and other neurodegenerative diseases. Plasma biomarkers of neurodegeneration and neuroinflammation hold utility in risk prediction and diagnosis of neurodegenerative disease and other neuropathology, but there remains a paucity of data in the T1D population. This study quantified plasma levels of biomarkers of neurodegeneration and neuroinflammation [phosphorylated tau-181 (pTau-181), total tau (Tau), amyloid beta 42\/amyloid beta 40 (A\u03b242\/40), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)], and tested associations with T1D and related characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional analysis of a subset of participants from the Coronary Artery Calcification in Type 1 Diabetes study included adults with and without T1D. Biomarker levels were quantified using Quanterix Simoa, then log-transformed and analyzed using linear regression models adjusted for age, body mass index (BMI), race and ethnicity, smoking status, and estimated glomerular filtration rate (eGFR). A subsequent sensitivity analysis included diabetic retinopathy (DR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>136 adults with T1D (n=90, age 52 years, 58% female, average HbA1c 7.7%) and without T1D (n=46, age 53 years, 57% female, average HbA1c 5.4%) were included. In fully adjusted models, T1D was associated with higher pTau-181 [estimate (pg\/mL) 1.221, (95% confidence interval 1.003, 1.486) p=0.046], GFAP [1.296 (1.129, 1.489), p&amp;lt;0.001], and NfL [1.355 (1.162, 1.579), p&amp;lt;0.001], relative to adults without T1D. In the sensitivity analysis, relative to adults without T1D, T1D with moderate\/severe DR was associated with higher pTau-181 [1.330 (1.063, 1.663), p=0.013], GFAP [1.369 (1.653, 1.608), p&amp;lt;0.001], and NfL [1.495 (1.252, 1.786), p&amp;lt;0.001], and T1D with none\/mild DR was associated with higher GFAP [1.228 (1.046, 1.442), p=0.013] and NfL [1.235 (1.037, 1.470), p=0.018]. As compared to T1D with none\/mild DR, T1D with moderate\/severe DR was associated with higher NfL [1.211 (1.011, 1.451), p=0.038]. Across both models, eGFR was inversely associated with pTau-181, NfL, and Tau (p&amp;lt;0.05 for all).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>T1D is associated with a greater burden of plasma biomarkers of neurodegeneration and neuroinflammation, and microvascular complications such as DR and impaired kidney function may contribute to this burden. Further study is needed to fully characterize the interplay between these biomarkers and neuropathology in T1D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1860993","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:40Z","timestamp":1784699560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Type 1 diabetes is associated with higher plasma levels of biomarkers of neurodegeneration and neuroinflammation"],"prefix":"10.3389","volume":"17","author":[{"given":"Meghan E.","family":"Pauley","sequence":"first","affiliation":[{"name":"Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Coughlan","sequence":"additional","affiliation":[{"name":"University of Colorado Alzheimer\u2019s and Cognition Center, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]},{"name":"Department of Neurology, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Dong","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bucca","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailey","family":"Tanner","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chartier-Logan","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L. B.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]},{"name":"Section of Endocrinology, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet K.","family":"Snell-Bergeon","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100944","article-title":"Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies","volume":"55","author":"Xue","year":"2019","journal-title":"Ageing Res Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.10.024","article-title":"An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer's disease","volume":"124","author":"Zhang","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.09.005","article-title":"Diabetes: a tipping point in neurodegenerative diseases","volume":"29","author":"Santiago","year":"2023","journal-title":"Trends Mol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-023-00462-8","article-title":"A nationwide cohort study on diabetes severity and risk of Parkinson disease","volume":"9","author":"Han","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12632","article-title":"Association between diabetes and amyotrophic lateral sclerosis in Sweden","volume":"22","author":"Mariosa","year":"2015","journal-title":"Eur J Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2438","article-title":"Brain structure among middle-aged and older adults with long-standing type 1 diabetes in the DCCT\/EDIC study","volume":"45","author":"Jacobson","year":"2022","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004024","article-title":"Increased incidence of neurodegenerative diseases in Finnish individuals with type 1 diabetes","volume":"12","author":"Satuli-Autere","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7566","DOI":"10.3390\/ijms26157566","article-title":"The inflammatory bridge between type 2 diabetes and neurodegeneration: a molecular perspective","volume":"26","author":"Kacem","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.089136","article-title":"The direct effect of type 2 diabetes on neurodegenerative processes in the absence of other cardiovascular risk factors","volume":"20","author":"Nowell","year":"2024","journal-title":"Alzheimer's Dementia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.07.002","article-title":"Relationship between diabetic retinopathy and systemic neurodegenerative diseases: a systematic review and meta-analysis","volume":"6","author":"Pedersen","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jalz.2018.06.2856","article-title":"Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease","volume":"15","author":"Lee","year":"2019","journal-title":"Alzheimers Dement"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3233\/aiad230037","article-title":"Diabetic retinopathy predicts risk of Alzheimer's disease: a Danish registry-based nationwide cohort study","volume":"86","author":"Pedersen","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23678","article-title":"Proteomic analysis of early diabetic retinopathy reveals mediators of neurodegenerative brain diseases","volume":"59","author":"Sundstrom","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1522014113","article-title":"Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus","volume":"113","author":"Sohn","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40001-023-01628-z","article-title":"Causal relationships between type 1 diabetes mellitus and Alzheimer\u2019s disease and Parkinson\u2019s disease: a bidirectional two-sample Mendelian randomization study","volume":"29","author":"Geng","year":"2024","journal-title":"Eur J Med Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29424","article-title":"Potential protective link between type I diabetes and Parkinson's disease risk and progression","volume":"38","author":"Senkevich","year":"2023","journal-title":"Movement Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020542","article-title":"Associations between diabetes mellitus and neurodegenerative diseases","volume":"26","author":"Szablewski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3333-6","article-title":"Cerebrospinal fluid levels of Alzheimer\u2019s disease biomarkers in middle-aged patients with type 1 diabetes","volume":"57","author":"Ouwens","year":"2014","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/wad.0000000000000230","article-title":"Diabetic retinopathy and dementia in type 1 diabetes","volume":"32","author":"Rodill","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy as a potential marker of Parkinson\u2019s disease: a register-based cohort study","volume":"3","author":"Larsen","year":"2021","journal-title":"Brain Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer's Dementia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03834-0","article-title":"The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging","volume":"31","author":"Imam","year":"2025","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105805","article-title":"Comparative performance of plasma pTau181\/A\u03b242, pTau217\/A\u03b242 ratios, and individual measurements in detecting brain amyloidosis","volume":"117","author":"Lehmann","year":"2025","journal-title":"eBioMedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00234-5","article-title":"Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis","volume":"10","author":"Ding","year":"2021","journal-title":"Transl Neurodegener"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-0659","article-title":"CSF and plasma A\u03b242\/40 across Alzheimer\u2019s disease continuum: comparison of two ultrasensitive Simoa\u00ae assays targeting distinct amyloid regions","volume":"62","author":"Wojda\u0142a","year":"2024","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330709","article-title":"Elevated plasma p-tau181 levels unrelated to Alzheimer\u2019s disease pathology in amyotrophic lateral sclerosis","volume":"94","author":"Vacchiano","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","article-title":"Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease","volume":"8","author":"Batzu","year":"2022","journal-title":"NPJ Parkinson's Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.942629","article-title":"Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis","volume":"14","author":"Chen","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2021.02.012","article-title":"Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease","volume":"103","author":"Bettcher","year":"2021","journal-title":"Neurobiol Aging"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.11.2833","article-title":"Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? : the Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study","volume":"52","author":"Dabelea","year":"2003","journal-title":"Diabetes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1017\/s1368980023000848","article-title":"Ultra-processed food consumption and obesity indicators in individuals with and without type 1 diabetes mellitus: a longitudinal analysis of the prospective Coronary Artery Calcification in Type 1 Diabetes (CACTI) cohort study","volume":"26","author":"Pang","year":"2023","journal-title":"Public Health Nutr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer's disease","volume":"390","author":"Jia","year":"2024","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease","volume":"17","author":"Simren","year":"2021","journal-title":"Alzheimers Dement"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264279","article-title":"A head-to-head comparison between plasma pTau181 and tau PET along the Alzheimer\u2019s disease continuum","volume":"64","author":"Coomans","year":"2023","journal-title":"J Nucl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross-sectional and longitudinal study in the AIBL cohort","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimer's Dementia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.832700","article-title":"Non-linear character of plasma amyloid beta over the course of cognitive decline in Alzheimer's continuum","volume":"14","author":"Pan","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3233\/jad-180140","article-title":"Elevation of plasma amyloid-\u03b2 level is more significant in early stage of cognitive impairment: a population-based cross-sectional study","volume":"64","author":"Wang","year":"2018","journal-title":"J Alzheimer\u2019s Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000505435","article-title":"Changes in plasma amyloid and tau in a longitudinal study of normal aging, mild cognitive impairment, and Alzheimer's disease","volume":"48","author":"Chen","year":"2019","journal-title":"Dement Geriatr Cognit Disord"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.119.024941","article-title":"Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus","volume":"50","author":"Korley","year":"2019","journal-title":"Stroke"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-7568(20)30061-1","article-title":"Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study","volume":"2","author":"Verberk","year":"2021","journal-title":"Lancet Healthy Longevity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/endocrines5020014","article-title":"Biomarkers of neurodegeneration and Alzheimer\u2019s disease neuropathology in adolescents and young adults with youth-onset type 1 or type 2 diabetes: a proof-of-concept study","volume":"5","author":"Shapiro","year":"2024","journal-title":"Endocrines"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0229","article-title":"Plasma biomarkers of brain injury and their association with brain MRI and cognition in type 1 diabetes","volume":"47","author":"Karger","year":"2024","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70029","article-title":"ATN blood biomarkers are related to digital cognitive assessment in type 1 diabetes","volume":"16","author":"Fonseca","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12466","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities","volume":"18","author":"Syrjanen","year":"2022","journal-title":"Alzheimers Dement"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance","volume":"19","author":"Pichet Binette","year":"2023","journal-title":"Alzheimer's Dementia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214446","article-title":"Kidney function, Alzheimer disease blood biomarkers, and dementia risk in community-dwelling older adults","volume":"106","author":"Gasparini","year":"2026","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05846-8","article-title":"Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy","volume":"66","author":"Maalmi","year":"2023","journal-title":"Diabetologia"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-023-02076-1","article-title":"Serum glial fibrillary acidic protein and neurofilament light chain as biomarkers of retinal neurodysfunction in early diabetic retinopathy: results of the EUROCONDOR study","volume":"60","author":"Hern\u00e1ndez","year":"2023","journal-title":"Acta Diabetol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1860993\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:41Z","timestamp":1784699561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1860993\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1860993"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1860993","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1860993"}}